<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="related to the cardiovascular field. 4.1. Antiviral therapies Remdesivir (GS-5734)," exact="adenosine" post="analogue, is a prodrug which is metabolized to its"/>
 <result pre="in COVID-19 patients with different disease severity (https://www.gilead.com/purpose/advancing-global-health/covid-19/remdesivir-clinical-trials). Lopinavir and" exact="ritonavir" post="were two protease inhibitor which was used to treat"/>
 <result pre="cardiovascular disease.24 4.2. Chloroquine/hydroxychloroquine Evidences suggested that the antimalarial drugs" exact="chloroquine" post="and hydroxychloroquine might exert potent antiviral and anti-inflammatory effects.40"/>
 <result pre="4.2. Chloroquine/hydroxychloroquine Evidences suggested that the antimalarial drugs chloroquine and" exact="hydroxychloroquine" post="might exert potent antiviral and anti-inflammatory effects.40 Chloroquine and"/>
 <result pre="chloroquine and hydroxychloroquine might exert potent antiviral and anti-inflammatory effects.40" exact="Chloroquine" post="and hydroxychloroquine are rapidly protonated and concentrated in endosomes"/>
 <result pre="hydroxychloroquine might exert potent antiviral and anti-inflammatory effects.40 Chloroquine and" exact="hydroxychloroquine" post="are rapidly protonated and concentrated in endosomes and therefore"/>
 <result pre="of the viral S protein. In vitro study showed both" exact="chloroquine" post="and hydroxychloroquine decrease SARS-CoV-2 replication in cultured cells and"/>
 <result pre="viral S protein. In vitro study showed both chloroquine and" exact="hydroxychloroquine" post="decrease SARS-CoV-2 replication in cultured cells and hydroxychloroquine was"/>
 <result pre="chloroquine and hydroxychloroquine decrease SARS-CoV-2 replication in cultured cells and" exact="hydroxychloroquine" post="was more potent than chloroquine.33,41 In a small single-arm"/>
 <result pre="small single-arm study of patients with confirmed COVID-19, treatment with" exact="hydroxychloroquine" post="was associated with a significant difference in clearing of"/>
 <result pre="to 6 days when compared with untreated controls. Moreover, combining" exact="hydroxychloroquine" post="with azithromycin showed even more efficient virus elimination in"/>
 <result pre="days when compared with untreated controls. Moreover, combining hydroxychloroquine with" exact="azithromycin" post="showed even more efficient virus elimination in present observation.42"/>
 <result pre="accepted worldwide and prophylactic usage had also been discussed recently.44" exact="Chloroquine" post="and hydroxychloroquine can cause QT prolongation, and cautious monitoring"/>
 <result pre="and prophylactic usage had also been discussed recently.44 Chloroquine and" exact="hydroxychloroquine" post="can cause QT prolongation, and cautious monitoring was crucial"/>
 <result pre="monitoring was crucial especially in the combination usage with azithromycin." exact="Chloroquine" post="and hydroxychloroquine can also cause rare complications including cardiomyopathy,"/>
 <result pre="crucial especially in the combination usage with azithromycin. Chloroquine and" exact="hydroxychloroquine" post="can also cause rare complications including cardiomyopathy, both systolic"/>
 <result pre="COVID-19 should be addressed. Evidences suggested that prehospital use of" exact="aspirin" post="use was associated a lower risk of for developing"/>
 <result pre="All P2Y12 inhibitors reduce platelet-leukocyte aggregates and platelet-derived pro-inflammatory cytokines." exact="Ticagrelor" post="is unique in having the most potent anti-inflammatory properties"/>
 <result pre="nucleoside transporter 1 (ENT1), which contributes to inhibition of cellular" exact="adenosine" post="uptake. The XANTHIPPE trial, as well as post hoc"/>
 <result pre="hoc analyses of PLATO study showed encouraging clinical benefit of" exact="ticagrelor" post="in the management of pneumonia by preventing the complications"/>
 <result pre="provide evidence supports a net benefit of aspirin-free strategies (reduce" exact="aspirin" post="duration to 1-3 months) after PCI for patients at"/>
 <result pre="effects of statin should still be monitored since myalgia, increased" exact="creatine" post="phosphokinase, rhabdomyolysis, and acute kidney injury do occur in"/>
 <result pre="and should also be carefully accessed during clinical practice.61 4.6." exact="Amiodarone" post="In a retrospective reviews of COVID-19 patients treated in"/>
 <result pre="in vitro spreading of SARS coronavirus. In vitro study showed" exact="amiodarone" post="inhibited SARS-CoV infection and spreading via altering the late"/>
 <result pre="virus through endosomes.63 Extrapolating current evidence, administration of prophylactic intravenous" exact="amiodarone" post="to mitigate the risk of late sudden cardiac arrest"/>
 <result pre="in COVID-19 cardiogenic shock.Eur J Heart Fail2020;22:911â€&quot;5.32275347 33.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="arbidol for COVID-19: a randomized clinical trial.medRxiv. 2020Doi:10.1101/2020.03.17.20037432. 40.SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of" exact="chloroquine" post="on viral infections: an old drug against todayâ€™s diseases?Lancet"/>
 <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2).Clin Infect Dis2020Doi:10.1093/cid/ciaa237. 42.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="of an open-label non-randomized clinical trial.Int J Antimicrob Agents2020Doi:10.1016/j.ijantimicag.2020.105949. 43.GaoJTianZYangXBreakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
 <result pre="of COVID-19 associated pneumonia in clinical studies.Biosci Trends2020;14:72â€&quot;3.32074550 44.PrincipiNEspositoSChloroquine or" exact="hydroxychloroquine" post="for prophylaxis of COVID-19.Lancet Infect Dis2020Doi:10.1016/S1473-3099(20)30296-6. 45.ChatreCRoubilleFVernhetHJorgensenCPersYMCardiac complications attributed"/>
 <result pre="for prophylaxis of COVID-19.Lancet Infect Dis2020Doi:10.1016/S1473-3099(20)30296-6. 45.ChatreCRoubilleFVernhetHJorgensenCPersYMCardiac complications attributed to" exact="chloroquine" post="and hydroxychloroquine: a systematic review of the literature.Drug Saf2018;41:919â€&quot;31.29858838"/>
 <result pre="50.StoreyRFJamesSKSiegbahnAVarenhorstCHeldCYcasJet al.Lower mortality following pulmonary adverse events and sepsis with" exact="ticagrelor" post="compared to clopidogrel in the PLATO study.Platelets2014;25:517â€&quot;25.24127651 51.YilmazSKiliÃ§OYaylaliYTDiffuse alveolar"/>
 <result pre="following pulmonary adverse events and sepsis with ticagrelor compared to" exact="clopidogrel" post="in the PLATO study.Platelets2014;25:517â€&quot;25.24127651 51.YilmazSKiliÃ§OYaylaliYTDiffuse alveolar hemorrhage associated with"/>
 <result pre="clopidogrel in the PLATO study.Platelets2014;25:517â€&quot;25.24127651 51.YilmazSKiliÃ§OYaylaliYTDiffuse alveolar hemorrhage associated with" exact="ticagrelor" post="therapy after percutaneous coronary intervention.Anatol J Cardiol2018;20:60â€&quot;1.29952365 52.ToyotaTShiomiHMorimotoTNatsuakiMKimuraTShort versus"/>
</results>
